Anxiety Drug Recalled

Direct Rx is recalling several lots of alprazolam due to cross-contamination concerns, according to the April 12, 2023, US Food and Drug Administration (FDA) Enforcement Report. 

The recall affects the following products, which were packaged and distributed throughout the United States by Direct Rx, Dawsonville, Georgia:

• alprazolam, 0.5 mg, 30 tabs per bottle (NDC 72189-0240-30), from lot 11AP2219 (Exp. 4/30/23);
• alprazolam, 1 mg, 30 tabs per bottle (NDC 72189-213-30), from lot 03FE2318 (Exp. 8/31/24);
• alprazolam, 1 mg, 60 tabs per bottle (NDC 72189-213-60), from lots 27FE2315, 28FE2313, 02MA2306, 21SE2201, 16NO2216, 17NO2216, and 24FA2314 (Exp. 8/31/24), 17FE2203, 12AP2204, and 17MA2205 (Exp. 3/31/23), 21JU2206, 22JU2220, and 12JY2206 (Exp. 5/31/23), 10AU2209 (Exp. 6/30/23), 14DE2215 (Exp. 9/30/24), and 05JA2304 and 27JA2301 (Exp. 11/30/24); and
• alprazolam, 2 mg, 60 tabs per bottle (NDC 72189-121-60), from lots 03FE2319 (Exp. 2/28/25) and 13MY2217 (Exp. 5/31/23).

Direct Rx voluntarily initiated the recall March 22, 2023. On April 6, 2023, the FDA designated the recall Class II, communicating use of the drug may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.

Alprazolam is a prescription medication used to treat patients with anxiety and panic disorder.